Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
Completed · Phase 1
Conditions studied: Osteoporosis
In brief
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity profile of romosozumab after a single 210 mg subcutaneous dose in healthy participants and patients with stage 4 renal impairment (RI) or stage 5 RI requiring hemodialysis.
Key facts
- Study ID
- NCT01833754
- Run by
- Amgen
- People needed
- 24
- Starts
- 2013-04-22
- Expected to finish
- 2014-02-19
- Last updated by the study team
- 2022-07-22
Who can join
Age: 50 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Research Site — Tempe, Arizona, United States
- Research Site — Los Angeles, California, United States
- Research Site — Denver, Colorado, United States
- Research Site — Pembroke Pines, Florida, United States
- Research Site — Orangeburg, South Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.